Corient Private Wealth LP Makes New Investment in Bicara Therapeutics Inc. $BCAX

Corient Private Wealth LP purchased a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 36,683 shares of the company’s stock, valued at approximately $1,089,000. Corient Private Wealth LP owned 0.06% of Bicara Therapeutics at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC purchased a new position in shares of Bicara Therapeutics in the first quarter valued at $248,000. Woodline Partners LP boosted its position in shares of Bicara Therapeutics by 26.5% in the 1st quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after buying an additional 72,998 shares in the last quarter. Geode Capital Management LLC grew its stake in Bicara Therapeutics by 36.8% in the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after acquiring an additional 180,833 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Bicara Therapeutics by 26.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock valued at $255,000 after acquiring an additional 5,664 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BCAX shares. Citigroup reiterated a “market outperform” rating on shares of Bicara Therapeutics in a research report on Friday, August 21st. The Goldman Sachs Group upped their target price on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Morgan Stanley increased their target price on Bicara Therapeutics from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. BMO Capital Markets started coverage on Bicara Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating and a $35.00 price target for the company. Finally, BTIG Research boosted their price target on Bicara Therapeutics from $28.00 to $39.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.64.

Bicara Therapeutics Trading Down 0.7%

NASDAQ BCAX opened at $23.17 on Friday. The business’s 50-day moving average price is $26.48 and its 200 day moving average price is $22.68. Bicara Therapeutics Inc. has a twelve month low of $10.30 and a twelve month high of $30.99. The company has a market capitalization of $1.53 billion, a PE ratio of -7.47 and a beta of -0.82.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.82). Equities analysts predict that Bicara Therapeutics Inc. will post -3.45 EPS for the current year.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, CFO Ivan Hyep sold 12,500 shares of Bicara Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.97, for a total value of $349,625.00. Following the transaction, the chief financial officer owned 129,855 shares in the company, valued at $3,632,044.35. This trade represents a 8.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 18,750 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $524,625.00. Following the sale, the chief operating officer directly owned 181,641 shares of the company’s stock, valued at $5,082,315.18. This represents a 9.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 108,000 shares of company stock worth $3,079,236. 13.80% of the stock is owned by company insiders.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.